Cambrex (CBM) Stock Price, News & Analysis

Company Overview

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms. The company serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.

Key Stats

• Today's Range: $59.99 to $59.99
• 50-Day Range: $59.99 to $59.99
• 52-Week Range: $33.80 to $60.29
• Volume: N/A
• Average Volume: 218,726 shs
• Market Capitalization: $2.02 billion
• P/E Ratio: 21.66
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CBM Stock Analysis - Frequently Asked Questions

How were Cambrex's earnings last quarter?

Cambrex Co. (NYSE:CBM) released its quarterly earnings results on Thursday, August, 2nd. The biotechnology company reported $0.74 earnings per share for the quarter, beating analysts' consensus estimates of $0.69 by $0.05. The business's revenue was up 13.0% on a year-over-year basis.

What other stocks do shareholders of Cambrex own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cambrex investors own include Bristol-Myers Squibb (BMY), Illumina (ILMN), AbbVie (ABBV), Meta Platforms (META), CVS Health (CVS), Gilead Sciences (GILD) and NVIDIA (NVDA).

Company Calendar

• Last Earnings: 8/02/2018
• Today: 4/03/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NYSE:CBM
• CIK: 820081
• Web: www.cambrex.com
• Phone: 201-804-3000
• Fax: N/A
• Employees: 1,732
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): $2.77
• Trailing P/E Ratio: 21.66
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $92.41 million
• Net Margins: 5.96%
• Pretax Margin: N/A
• Return on Equity: 5.38%
• Return on Assets: 2.50%

Debt

• Debt-to-Equity Ratio: 0.76
• Current Ratio: 2.37
• Quick Ratio: 1.70

Sales & Book Value

• Annual Sales: $532.09 million
• Price / Sales: 3.80
• Cash Flow: $3.91 per share
• Price / Cash Flow: 15.36
• Book Value: $19.48 per share
• Price / Book: 3.08

Miscellaneous

• Outstanding Shares: 33,720,000
• Free Float: N/A
• Market Cap: $2.02 billion
• Optionable: Optionable
• Beta: 2.14